Market Overview:
The global Japanese encephalitis vaccine market is expected to grow at a CAGR of 9.5% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as rising incidence of Japanese encephalitis, increasing awareness about the disease and its prevention, and growing demand for vaccines in developing countries. However, the high cost of vaccination may restrain the growth of this market to some extent. Based on type, the global Japanese encephalitis vaccine market is segmented into inactivated vaccine and live attenuated vaccine. Inactivated vaccines are further sub-segmented into monovalent vaccines and multivalent vaccines. Live attenuated vaccines are further sub-segmented into chimeric viruses (CV) JE vaccine and recombinant JE virus (rJEV) vaccine. Based on application, the global Japanese encephalitisvaccine market is segmented into public sector and private sector segments. Public sector includes government hospitals/clinics while private sector includes corporate hospitals/clinics).
 Vaccine Industry Outlook.svg)
Product Definition:
Japanese Encephalitis vaccine is a vaccine used to prevent Japanese encephalitis. It is recommended for people who are going to live in or travel to areas where the disease is common.
Inactivated Vaccine:
Inactivated vaccines are made by the process of heat-treatment (pasteurization) to inactivate the virus. The vaccine is usually made from weakened or killed viruses, which can cause disease if consumed. In some cases, live attenuated vaccines may also be used.
• Introduction & usage • Vaccine growth factors.
Live Attenuated Vaccine:
Live Attenuated Vaccine (LAV) is a vaccine that uses the principle of live attenuation. It helps in stimulating the body's immune system to produce antibodies against virus particles thus preventing disease spread. LAVs are used for JE, Hepatitis B and C, influenza (flu), and rabies among others.
Application Insights:
The public health application segment held the largest share of over 70.0% in 2017. The rising number of JE cases has resulted in increased focus on immunization against this disease, which is driving the demand for JE vaccine among public health authorities worldwide. According to WHO, an estimated 10-50 million people are affected by Japanese encephalitis every year with a mortality rate of around 5%.
In addition, according to data published by the National Center for Biotechnology Information (NCBI) in 2018 regarding incidence and mortality rates of Japanese encephalitis across various age groups, it can be estimated that around 40-60 thousand people die due to this disease every year globally and about 1 lac - 2 lac children are affected with severe neurological disorders due to Japanese encephalitis infection annually. These factors indicate that there is significant unmet healthcare need regarding prevention & control of Japanese Encephalitis and thus drive demand for these vaccines globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong research base and higher awareness levels pertaining to JE vaccination among the population are some of the major factors contributing to its largest share. Moreover, government initiatives for conducting clinical trials on Japanese encephalitis vaccine along with high investment by manufacturers in this region is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to increasing incidence rates of JE coupled with rising target population group (children below 15 years). Furthermore, growing target disease burden coupled with improving healthcare infrastructure will also support regional market expansion during the same period. Japan accounted for a significant share due to favorable climatic conditions that enhance mosquito breeding and increase vector-borne diseases prevalence within this country leading towards an increased demand for vaccines against these diseases globally as well as domestically across Asia Pacific countries such as India & China & Indonesia etc.
Growth Factors:
- Increasing awareness about the disease and its prevention among people, especially in developing countries
- Government initiatives for vaccination programs in endemic areas
- Growing demand for preventive measures against JE infections
- Technological advancements in vaccine development and production processes
- Rising number of travelers to endemic areas
Scope Of The Report
Report Attributes
Report Details
Report Title
Japanese Encephalitis (JE) Vaccine Market Research Report
By Type
Inactivated Vaccine, Live Attenuated Vaccine
By Application
Public, Private
By Companies
GSK, Sanofi, Chengdu institute of biologica, Wuhan Institute of Biological, Lanzhou Institute of Biological, Beijing Taitan, Valneva, Bharat Biotech, Biological E. Limited, Liaoning Chengda
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Japanese Encephalitis (JE) Vaccine Market Report Segments:
The global Japanese Encephalitis (JE) Vaccine market is segmented on the basis of:
Types
Inactivated Vaccine, Live Attenuated Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Public, Private
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Sanofi
- Chengdu institute of biologica
- Wuhan Institute of Biological
- Lanzhou Institute of Biological
- Beijing Taitan
- Valneva
- Bharat Biotech
- Biological E. Limited
- Liaoning Chengda
 Vaccine Market Overview.svg)
Highlights of The Japanese Encephalitis (JE) Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inactivated Vaccine
- Live Attenuated Vaccine
- By Application:
- Public
- Private
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Japanese Encephalitis (JE) Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Vaccine Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Japanese Encephalitis (JE) vaccine is a vaccine used to prevent Japanese Encephalitis.
Some of the major players in the japanese encephalitis (je) vaccine market are GSK, Sanofi, Chengdu institute of biologica, Wuhan Institute of Biological, Lanzhou Institute of Biological, Beijing Taitan, Valneva, Bharat Biotech, Biological E. Limited, Liaoning Chengda.
The japanese encephalitis (je) vaccine market is expected to register a CAGR of 9.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Japanese Encephalitis (JE) Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Japanese Encephalitis (JE) Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Japanese Encephalitis (JE) Vaccine Market - Supply Chain
4.5. Global Japanese Encephalitis (JE) Vaccine Market Forecast
4.5.1. Japanese Encephalitis (JE) Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Japanese Encephalitis (JE) Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Japanese Encephalitis (JE) Vaccine Market Absolute $ Opportunity
5. Global Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
5.3.1. Inactivated Vaccine
5.3.2. Live Attenuated Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
6.3.1. Public
6.3.2. Private
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Japanese Encephalitis (JE) Vaccine Demand Share Forecast, 2019-2026
9. North America Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
9.4.1. Public
9.4.2. Private
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
9.7.1. Inactivated Vaccine
9.7.2. Live Attenuated Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Japanese Encephalitis (JE) Vaccine Demand Share Forecast, 2019-2026
10. Latin America Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
10.4.1. Public
10.4.2. Private
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
10.7.1. Inactivated Vaccine
10.7.2. Live Attenuated Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Japanese Encephalitis (JE) Vaccine Demand Share Forecast, 2019-2026
11. Europe Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
11.4.1. Public
11.4.2. Private
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
11.7.1. Inactivated Vaccine
11.7.2. Live Attenuated Vaccine
11.8. Basis Point Share (BPS) Analyis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Japanese Encephalitis (JE) Vaccine Demand Share, 2019-2026
12. Asia Pacific Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
12.4.1. Public
12.4.2. Private
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
12.7.1. Inactivated Vaccine
12.7.2. Live Attenuated Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Japanese Encephalitis (JE) Vaccine Demand Share, 2019-2026
13. Middle East & Africa Japanese Encephalitis (JE) Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Application
13.4.1. Public
13.4.2. Private
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Japanese Encephalitis (JE) Vaccine Market Size and Volume Forecast by Type
13.7.1. Inactivated Vaccine
13.7.2. Live Attenuated Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Japanese Encephalitis (JE) Vaccine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Japanese Encephalitis (JE) Vaccine Market: Market Share Analysis
14.2. Japanese Encephalitis (JE) Vaccine Distributors and Customers
14.3. Japanese Encephalitis (JE) Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Chengdu institute of biologica
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Wuhan Institute of Biological
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lanzhou Institute of Biological
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Beijing Taitan
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Valneva
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bharat Biotech
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biological E. Limited
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Liaoning Chengda
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
